SHP2 Inhibition Overcomes RTK-mediated Pathway Re-Activation in KRAS Mutant Tumors Treated With MEK Inhibitors

Molecular Cancer Therapeutics - United States
doi 10.1158/1535-7163.mct-18-0852
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

SHP2 Inhibition Prevents Adaptive Resistance to MEK Inhibitors in Multiple Cancer Models

Cancer Discovery
Oncology
2018English

Combined MEK and BCL-XL Inhibition Kills KRAS -Mutant Cells

Cancer Discovery
Oncology
2012English

Shipping Out MEK Inhibitor Resistance With SHP2 Inhibitors

Cancer Discovery
Oncology
2018English

RAF Dimer Inhibition Enhances the Antitumor Activity of MEK Inhibitors in K‐RAS Mutant Tumors

Molecular Oncology
Cancer ResearchMedicineOncologyGeneticsMolecular Medicine
2020English

Erratum: Mechanism of MEK Inhibition Determines Efficacy in Mutant KRAS- Versus BRAF-driven Cancers

Nature
Multidisciplinary
2013English

Combination PI3K/MEK Inhibition Promotes Tumor Apoptosis and Regression in PIK3CA Wild-Type, KRAS Mutant Colorectal Cancer

Cancer Letters
Cancer ResearchOncology
2014English

Synthetic Lethal Interaction of Combined BCL-XL and MEK Inhibition Promotes Tumor Regressions in KRAS Mutant Cancer Models

Cancer Cell
Cancer ResearchOncologyCell Biology
2013English

Allosteric Inhibitors Target KRAS in a Mutant-Specific Manner

Cancer Discovery
Oncology
2013English

Effective Use of PI3K and MEK Inhibitors to Treat Mutant Kras G12D and PIK3CA H1047R Murine Lung Cancers

Nature Medicine
BiochemistryMedicineGeneticsMolecular Biology
2008English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy